Phoebe Cancer Center at Phoebe Putney...

Georgia's Online Cancer Information Center

Find A Treatment Site

Phoebe Cancer Center at Phoebe Putney Memorial Hospital

The Phoebe Cancer Center at Phoebe Putney Memorial Hospital is located in Albany, Georgia. The center is fully accredited by the American College of Surgeons Commission on Cancer as a Community Hospital Comprehensive Cancer Program. The center is also accredited by the American College of Radiology (ACR). There are eleven physicians practicing at the Phoebe Cancer Center, including the following specialties: hematology oncology, radiation oncology and surgical oncology. Services offered include: counseling, support groups, nutrition, oncology wellness program, lymphedema clinic, breast cancer nurse navigator, transportation options, light house, inpatient unit, pastoral care, hospice, financial assistance, Carlton Breast Health Center and tumor registry. Each patient at the Phoebe Cancer Center has an entire team working for them, including doctors, certified oncology nurses, pharmacists, lab analysts, counselors and other medical professionals. The center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers.

Treatment Sites in Georgia

Clinical Trials in Georgia

An analysis of the Duffy Antigen Receptor for Chemokines/Atypical Chemokine Receptor 1 (DARC/ACKR1) and Risk of Triple Negative Breast Cancer (TNBC)
Cancer Type: Breast Cancer

Comparing Cytarabine + Daunorubicin Therapy versus Cytarabine + Daunorubicin + Venetoclax versus Venetoclax + Azacitidine in Younger Patients with Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Cancer Type: Leukemia

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
Cancer Type: Solid Tumor

Division of Cancer Prevention NH-DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type: Breast Cancer, Unknown Primary

Mobile Health for Adherence in Breast Cancer Patients
Cancer Type: Breast Cancer

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Cancer Type: Breast Cancer, Unknown Primary

MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Breast Cancer, Unknown Primary

ShortStop-HER2: 12 months vs. 6 months of HER2-targeted Medications for People with HER2+ Breast Cancer who Had a Pathologic Complete Response after Chemotherapy Plus Trastuzumab
Cancer Type: Breast Cancer, Unknown Primary

Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
Cancer Type: Breast Cancer, Unknown Primary

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) with IDH2 Mutation (A MyeloMATCH Treatment Trial)
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Breast Cancer, Unknown Primary

Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Cancer Type: Multiple Myeloma

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients with High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Cancer Type: Leukemia

Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Cancer Type: Leukemia
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.